SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/286119"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/286119" > Bronchodilator reve...

  • Jansson, ChristerUppsala universitet,Lung- allergi- och sömnforskning (författare)

Bronchodilator reversibility in asthma and COPD: findings from three large population studies

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2019-06-20
  • European Respiratory Society (ERS),2019

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/286119
  • https://gup.ub.gu.se/publication/286119URI
  • https://doi.org/10.1183/13993003.00561-2019DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-396637URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:142008679URI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Bronchodilator response (BDR) testing is used as a diagnostic method in obstructive airway diseases. The aim of this investigation was to compare different methods for measuring BDR in participants with asthma and chronic obstructive pulmonary disease (COPD) and to study to the extent to which BDR was related to symptom burden and phenotypic characteristics. Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were measured before and 15 min after 200 mu g of salbutamol in 35 628 subjects aged >= 16 years from three large international population studies. The subjects were categorised in three groups: current asthma (n=2833), COPD (n=1146) and no airway disease (n=31 649). Three definitions for flow-related reversibility (increase in FEV1) and three for volume-related reversibility (increase in FVC) were used. The prevalence of bronchodilator reversibility expressed as increase FEV1 >= 12% and 200 mL was 17.3% and 18.4% in participants with asthma and COPD, respectively, while the corresponding prevalence was 5.1% in those with no airway disease. In asthma, bronchodilator reversibility was associated with wheeze (OR 1.36, 95% CI 1.04-1.79), atopy (OR 1.36, 95% CI 1.04-1.79) and higher exhaled nitric oxide fraction, while in COPD neither flow- nor volume-related bronchodilator reversibility was associated with symptom burden, exacerbations or health status after adjusting for pre-bronchodilator FEV1. Bronchodilator reversibility was at least as common in participants with COPD as those with asthma. This indicates that measures of reversibility are of limited value for distinguishing asthma from COPD in population studies. However, in asthma, bronchodilator reversibility may be a phenotypic marker.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Malinovschi, Andrei,1978-Uppsala universitet,Integrativ Fysiologi(Swepub:uu)anmal535 (författare)
  • Amaral, A. F. S.Imperial Coll London, Natl Heart & Lung Inst, Populat Hlth & Occupat Dis, London, England,Univ Verona, Dept Diagnost & Publ Hlth, Unit Epidemiol & Med Stat, Verona, Italy (författare)
  • Accordini, S.Oregon Hlth & Sci Univ, Pulm & Crit Care Med, Portland, OR 97201 USA (författare)
  • Bousquet, J.Fdn FMC VIA LR, Montpellier, France;Euforea, Brussels, Belgium;Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergy Ctr Charite, Berlin, Germany (författare)
  • Buist, A. S. (författare)
  • Canonica, G. W.Humanitas Res Hosp, Personalized Med Clin Asthma & Allergy, Milan, Italy (författare)
  • Dahlen, B.Karolinska Institutet (författare)
  • Garcia-Aymerich, J.ISGlobal, Barcelona, Spain;UPF, Barcelona, Spain;CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain (författare)
  • Gnatiuc, L.Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Oxford, England;Univ Oxford, Nuffield Dept Populat Hlth, Epidemiol Studies Unit, Oxford, England (författare)
  • Kowalski, M. L.Med Univ Lodz, Dept Immunol & Allergy, Lodz, Poland (författare)
  • Patel, J.Imperial Coll London, Natl Heart & Lung Inst, Populat Hlth & Occupat Dis, London, England (författare)
  • Tan, W.Univ British Columbia, St Pauls Hosp Vancouver, Ctr Heart Lung Innovat, Vancouver, BC, Canada (författare)
  • Torén, Kjell,1952Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa, enheten för arbets-och miljömedicin,Institute of Medicine, Department of Public Health and Community Medicine, Section of Occupational and environmental medicine,Univ Gothenburg, Dept Occupat & Environm Med, Gothenburg, Sweden(Swepub:gu)xtorkj (författare)
  • Zuberbier, T. (författare)
  • Burney, P.Imperial Coll London, Natl Heart & Lung Inst, Populat Hlth & Occupat Dis, London, England (författare)
  • Jarvis, D.Imperial Coll London, Natl Heart & Lung Inst, Populat Hlth & Occupat Dis, London, England (författare)
  • Uppsala universitetLung- allergi- och sömnforskning (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:European Respiratory Journal: European Respiratory Society (ERS)54:30903-19361399-3003

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy